BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET

Rhea-AI Summary

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a conference call and webcast on April 26, 2023, at 4:30 p.m. ET to discuss its first-quarter 2023 financial results and provide a business update. CEO Jean-Jacques Bienaimé will lead the session, which can be accessed via the investor section of the BioMarin website. The U.S./Canada dial-in number is 800-831-4163 and the international number is 213-992-4616. Replay options will be available following the call. Founded in 1997, BioMarin focuses on developing therapies for rare genetic disorders, boasting eight commercial products that address unmet medical needs. The company’s innovative approach has produced a diverse pipeline aimed at delivering substantial benefits over existing treatments.

SAN RAFAEL, Calif., April 13, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26, at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: 800-831-4163
International Dial-in Number: 213-992-4616

U.S. / Canada Replay Dial-in Number: 800-645-7964
International Replay Dial-in Number: 757-849-6722
Playback ID: 9184#

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2023-financial-results-conference-call-and-webcast-on-wednesday-april-26-at-430pm-et-301796481.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

What is the date and time for BioMarin's Q1 2023 financial results conference call?

BioMarin will hold its Q1 2023 financial results conference call on April 26, 2023, at 4:30 p.m. ET.

How can I access the BioMarin Q1 2023 financial results conference call?

You can access the webcast via the investor section of the BioMarin website.

What is BioMarin's stock symbol?

BioMarin's stock symbol is BMRN.

What is the dial-in number for the BioMarin conference call?

The U.S./Canada dial-in number is 800-831-4163 and the international dial-in number is 213-992-4616.

What is BioMarin known for?

BioMarin is known for developing therapies for rare genetic disorders and has eight commercial therapies addressing unmet medical needs.